First, Clarisse Ribeiro, who joined in MM/2025, holds a degree in [to be completed], and specializes in [to be completed].
Next, Mohamed ALILI, a Doctor of Pharmacy since 2020 in Algeria, is currently completing an internship to validate his degree in France. He is involved in Quality Assurance and Regulatory Affairs under the direct supervision of Anne Walter.
Finally, we welcomed a second intern in May 2025. Swann Walch is completing his fifth-year pharmacy internship under the supervision of Stéphane Simon, contributing to business development and the integration of AI into company processes.
These new additions reflect the energy and momentum of both companies, their appeal to young talent, and their commitment to excellence, innovation, and knowledge sharing.
- Sector Growth: 2,700 companies, 75,600 employees, +21% revenue growth, and €1.4 billion in R&D investments (+10%).
- Challenges: Despite high startup rates, business failures are increasing. Financing remains critical, with strong support from Bpifrance.
- Employment: Slight decline in 2024, but 83% of companies plan to hire in 2025 (+2,000 jobs).
- Tech Focus: Digital health and AI are booming, with 450 companies using AI and 76% in the commercialization phase.
- Government Support: €682 million allocated by Bpifrance, focusing on mental health and prevention. Tax incentives like CIR and JEI benefit 86% of companies.
- Sector Insights: Biotech focuses on oncology, neurology, and infectious diseases. Medtech faces MDR challenges. Digital health is advancing diagnostics and patient monitoring.
- Outlook: The sector is set for growth, driven by innovation, partnerships, and public support, though financing and regulatory compliance remain key hurdles.
Stéphane Simon joins as VP, Chief Pharmaceutical Officer of IDD and CEO of Bio Valys Pharma. With 30 years of experience as a Qualified Person and a strong background in regulatory leadership, he will lead the development of a new strategic pillar focused on pharmaceutical commercialization.
Anne Walter takes on the role of Director of Pharmaceutical Affairs & Exploitation. With over three decades of experience in quality, pharmacovigilance, and compliance, she will strengthen IDD’s regulatory foundations and help shape its future strategic offerings.
Their appointments represent a significant milestone in IDD’s growth, reinforcing our expertise and expanding our capabilities for the years ahead.